Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.44 |
| ▸ | RARB | P10826 | 11/20 | 0.44 |
| ▸ | RXRB | P28702 | 10/20 | 0.44 |
| ▸ | RARG | P13631 | 10/20 | 0.44 |
| ▸ | RXRG | P48443 | 6/20 | 0.44 |
| ▸ | RARA | P10276 | 7/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24701909 | 0.81 | RARB (0.49) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL16523407 | 0.77 | RARB (0.74) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL5847316 | 0.76 | RARB (0.59) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL1615553 | 0.74 | RXRA (0.46) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL17911588 | 0.74 | RXRA (0.67) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL11599145 | 0.74 | RXRA (0.42) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL6779600 | 0.73 | RXRA (0.43) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7756501 | 0.73 | RARB (0.64) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL3169358 | 0.73 | HTR2A (0.46) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL4047286 | 0.73 | RXRA (0.46) | RXRARARBRXRBRARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000631-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | UNIVERSITY OF DURHAM (GB) | 2026-01-01 | — | — | US | disclosed |
| US-12344587-B2 | Synthetic retinoids for use in RAR activation | UNIVERSITY OF DURHAM (GB) | 2025-07-01 | — | — | US | disclosed |
| US-11807616-B2 | Organic compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-11-07 | — | — | US | disclosed |
| US-11807616-B2 | Organic compound, and electronic element and electronic device using same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-11-07 | — | — | US | disclosed |
| WO-2023172110-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172110-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2023-09-14 | — | — | WO | disclosed |
| US-20230265063-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265063-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-3911645-B1 | 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE | UNIV LILLE (FR) | 2022-12-07 | — | — | EP | disclosed |
| EP-4083029-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2012076842-A1 | SYNTHETIC RETINOIDS FOR CONTROL OF CELL DIFFERENTIATION | UNIVERSITY OF DURHAM (GB) | 2012-06-14 | — | — | WO | disclosed |
| EP-1453496-A4 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | FORMAN BARRY M (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1453496-A2 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003043581-A2 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| EP-0629604-B1 | Alicyclic phospholipase A2 inhibitors | BRISTOL MYERS SQUIBB CO (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0750619-A1 | HETERO-ANNULATED INDAZOLES | BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) | 1997-01-02 | — | — | EP | disclosed |
| US-5436369-A | Alicyclic phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0629604-A2 | Alicyclic phospholipase A2 inhibitors | Bristol-Myers Company (US) | 1994-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000631-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | RARB, RARA, RXRA | RXRA 3/4885RARB 1/4885RXRB 4/4885 |
| US-20230265063-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | PIEZO1, OR10J3, OR51E2 | RXRA 2012/4885RARB 2354/4885RXRB 2635/4885 |
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885RARB 181/4885RXRB 28/4885 |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885RARB 181/4885RXRB 28/4885 |
| US-11807616-B2 | Organic compound, and electronic element and electronic device using same | PIEZO1, OR10J3, OR51E2 | RXRA 2012/4885RARB 2354/4885RXRB 2635/4885 |
| US-12344587-B2 | Synthetic retinoids for use in RAR activation | RARA, RXRA, RARB | RXRA 2/4885RARB 3/4885RXRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.